<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00561132</url>
  </required_header>
  <id_info>
    <org_study_id>2002/252/129</org_study_id>
    <secondary_id>173/03/13</secondary_id>
    <secondary_id>FP-2003/073</secondary_id>
    <nct_id>NCT00561132</nct_id>
  </id_info>
  <brief_title>Study of Vanadium Supplement in Patients With Impaired Glucose Tolerance</brief_title>
  <official_title>Effect of Vanadium on Insulin Sensitivity in Patients With Impaired Glucose Tolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unidad de Investigacion Medica en Epidemiologia Clinica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondo para el Fomento a la Investigacion Medica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Doctorado en Farmacologia de la Universidad de Guadalajara</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Unidad de Investigacion Medica en Epidemiologia Clinica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate if the vanadium can improve the insulin sensitivity
      in patients with impaired glucose tolerance. Secondary purpose of this study was to assess
      changes on metabolic profile, weight and blood pressure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">November 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes on insulin sensitivity assessed with a euglycemic-hyperinsulinemic clamp technique</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes on metabolic profile</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on anthropometrical measures</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Prediabetic State</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vanadyl sulfate</intervention_name>
    <description>50 mg twice daily orally for a period of 4 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Vanadyl sulphate</other_name>
    <other_name>Vanadyl sulfate hydrate</other_name>
    <other_name>Vanadyl sulphate hydrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Magnesium oxide</intervention_name>
    <description>Validation of similar appearance and weight to the intervention component orally 1 unit (&lt;50 mg) twice daily for a period of 4 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Calcinated magnesia</other_name>
    <other_name>Calcined Magnesite</other_name>
    <other_name>Magnesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of impaired glucose tolerance

          -  Body mass index from 25 to 35 kg/m2

          -  History of type 2 diabetes mellitus in the first branch

        Exclusion Criteria:

          -  Taking medication with known effects on carbohydrate or insulin metabolism

          -  Thyroid diseases

          -  Hepatic diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omar Jacques-Camarena, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unidad de Investigacion Medica en Epidemiologia Clinica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel González-Ortiz, MD, MSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unidad de Investigacion Medica en Epidemiologia Clinica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Esperanza Martínez-Abundis, MD, MSc, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Unidad de Investigacion Medica en Epidemiologia Clinica</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unidad de Investigacion Medica en Epidemiologia Clinica, Hospital de Especialidades, UMAE, Centro Medico Nacional de Occidente</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44320</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2007</study_first_submitted>
  <study_first_submitted_qc>November 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2007</study_first_posted>
  <last_update_submitted>November 19, 2007</last_update_submitted>
  <last_update_submitted_qc>November 19, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2007</last_update_posted>
  <keyword>vanadium</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>impaired glucose tolerance</keyword>
  <keyword>triglycerides</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vanadyl sulfate</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Magnesium Oxide</mesh_term>
    <mesh_term>Vanadium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

